Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 127.50
Bid: 126.00
Ask: 129.00
Change: 0.00 (0.00%)
Spread: 3.00 (2.381%)
Open: 127.50
High: 127.50
Low: 127.50
Prev. Close: 127.50
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Nov 2020 16:32

RNS Number : 8887E
Diaceutics PLC
10 November 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Diaceutics Plc

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Danske Bank A/S

City and country of registered office (if applicable)

DK - 1092 Copenhagen

4. Full name of shareholder(s) (if different from 3.)v

Name

 

DANSKE INVEST MANAGEMENT COMPANY (SOCIÉTE ANONYME)/DANSKE INVEST FCP LUXEMBOURG

 

DANSKE INVEST FUND MANAGEMENT LTD./DANSKE INVEST FINLAND

 

PROXY VOTES SUPPLIED BY INVESTERINGSFORENINGEN DANSKE INVEST

 

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

09-11-2020

6. Date on which issuer notified (DD/MM/YYYY):

10-11-2020

7. Total positions of person(s) subject to the notification obligation4.77109

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.10

 

3.10

 

84,068,923.00

 

Position of previous notification (if

applicable)

 

N/A

 

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BJQTGV64

 

2,605,164.00

 

 

3.10

SUBTOTAL 8. A

2,605,164.00

 

3.10

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Danske Invest FCP Luxembourg

13, rue Edward Steichen

L-2540 Luxembourg

- A mutual fund under management of

Danske Invest Management Company (Société Anonyme)

13, rue Edward Steichen

L-2540 Luxembourg

- a subsidiary 100% owned by

Danske Bank International S.A,

13, rue Edward Steichen

L-2540 Luxembourg

- a subsidiary 100% owned by Danske Bank A/S

 

Danske Invest Finland

Hiililaiturinkuja 2, P.O. Box 1553,

FIN-00180 Helsinki

Finland

- a mutual fund under management of

Danske Invest Fund Management Ltd.

Hiililaiturinkuja 2, P.O. Box 1553,

FIN-00180 Helsinki

Finland

- a subsidiary 100% owned by

Danske Bank plc

Hiililaiturinkuja 2, P.O. Box 1568

00075 Danske Bank, Finland

- a subsidiary 100% owned by Danske Bank A/S

Proxy shares given to Danske Capital, a division of Danske Bank A/S (so no separate legal identity) by:

 

lnvesteringsforeningen Danske Invest

Parallelvej 17

DK-2800 Kgs. Lyngby

Denmark

10. In case of proxy voting, please identify:

Name of the proxy holder

DANSKE Capital, a division of Danske Bank A/S

The number and % of voting rights held

Danske Invest Europa Small cap

(1,076,798.00 shs/votings rights = 1.28%)

 

Danske Invest Europa Small cap AKK

(94,988.00 shs/votings rights = 0.11%)

The date until which the voting rights will be held

No set expiry date

11. Additional informationxvi

 

Place of completion

DK - 1092 Copenhagen K

Date of completion

10-11-2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLQBLFFBFLXFBB
Date   Source Headline
11th Jan 20227:00 amRNSTrading Update and Notice of Results
4th Jan 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
14th Dec 20217:00 amRNSContract Win
9th Dec 20217:00 amRNSTest Signal Launch and Contract Wins
1st Dec 20215:22 pmRNSPDMR Shareholding/Share Incentive Plan
9th Nov 20214:57 pmRNSPDMR Shareholding/Share Incentive Plan
1st Oct 20211:19 pmRNSPDMR Shareholding/Share Incentive Plan
1st Oct 202112:32 pmRNSHolding(s) in Company
28th Sep 20217:00 amRNSPurchase/Transfer of Shares and PDMR Shareholdings
21st Sep 20217:00 amRNSNominated as finalists for Health Tech Awards 2021
14th Sep 20217:00 amRNSHalf-year Report
13th Sep 20217:00 amRNSDXRX Platform Contract Win
8th Sep 20217:00 amRNSTwo new experts join the Diaceutics Advisory Panel
1st Sep 20217:00 amRNSPDMR Shareholding/Share Incentive Plan
31st Aug 20217:00 amRNSNotice of Investor Presentation
30th Jul 20214:54 pmRNSPDMR Shareholding/Share Incentive Plan
8th Jul 20217:00 amRNSTrading Update
1st Jul 20217:00 amRNSIssue of Share Options and PDMR Shareholdings
29th Jun 20214:56 pmRNSPDMR Shareholding/Share Incentive Plan
24th Jun 20217:00 amRNSNew Contract Wins
18th Jun 20217:00 amRNSPurchase of Shares and PDMR Shareholding
16th Jun 20217:00 amRNSCapital Markets Day and KPI Update
7th Jun 20216:23 pmRNSPDMR Shareholding/Share Incentive Plan
7th Jun 20217:00 amRNSNotice of Capital Markets Day
4th Jun 20217:00 amRNSPresenting data on COVID impact on cancer at ASCO
21st May 20211:49 pmRNSHolding(s) in Company
21st May 20217:00 amRNSChange of Adviser
19th May 20213:24 pmRNSResult of AGM
13th May 20217:00 amRNSLGC SeraCare Partnership
12th May 20215:58 pmRNSSale of Shares and PDMR Shareholding
5th May 20216:03 pmRNSHolding(s) in Company
4th May 20213:11 pmRNSSale of Shares and Director/PDMR Shareholding
30th Apr 202111:01 amRNSShare Incentive Plan
21st Apr 20217:00 amRNSNotice of AGM and posting of Annual Report
12th Apr 20217:00 amRNSNew Vice President of Operations in Asia
8th Apr 20219:49 amRNSTransfer of Shares and Director/PDMR Shareholding
7th Apr 20217:58 amRNSTransfer of Shares and Director/PDMR Shareholding
6th Apr 202111:12 amRNSIssue of Share Options/PDMR Shareholdings
1st Apr 20217:00 amRNSCOVID-19 Testing Data licensing agreement
30th Mar 20217:00 amRNSNew lease agreement and related party transaction
15th Mar 20217:00 amRNSFinal Results
8th Mar 20217:00 amRNSNotice of Results
4th Mar 202112:49 pmRNSNew Vice President of Finance appointment
21st Jan 20217:00 amRNSQuarterly media update
11th Jan 20219:56 amRNSHolding(s) in Company
11th Jan 20217:00 amRNSTrading update
22nd Dec 20207:01 amRNSDirectorate Change
22nd Dec 20207:00 amRNSDirectorate Change
10th Dec 20203:10 pmRNSHolding(s) in Company
17th Nov 20207:00 amRNSEuropean international award win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.